Clinical trials in older patients with cancer – typical challenges, possible solutions, and a paradigm of study design in breast cancer
Open Access
- 17 June 2024
- journal article
- review article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 63, 441-447
Abstract
Background and purpose: While the prevalence of older breast cancer patients is rapidly increasing, these patients are greatly underrepresented in clinical trials. We discuss barriers to recruitment of older patients to clinical trials and propose solutions on how to mitigate these challenges and design optimal clinical trials through the paradigm of IMPORTANT trial. Patients and methods: This is a narrative review of the current literature evaluating barriers to including older breast cancer patients in clinical trials and how mitigating strategies can be implemented in a pragmatic clinical trial. Results: The recognized barriers can be roughly divided into trial design-related (e.g. the adoption of strict inclusion criteria, the lack of pre-specified age-specific analysis), patient-related (e.g. lack of knowledge, valuation of the quality-of-life instead of survival, transportation issues), or physician-related (e.g. concern for toxicity). Several strategies to mitigate barriers have been identified and should be considered when designing a clinical trial dedicated to older patients with cancer. The pragmatic, de-centralized IMPORTANT trial focusing on dose optimization of CDK4/6 -inhibitors in older breast cancer patients is a paradigm of a study design where different mitigating strategies have been adopted. Interpretation: Because of the existing barriers, older adults in clinical trials are considerably healthier than the average older patients treated in clinical practice. Thus, the study results cannot be generalized to the older population seen in daily clinical practice. Broader inclusion/exclusion criteria, offering telehealth visits, and inclusion of patient-reported, instead of physician-reported outcomes may increase older patient participation in clinical trials.Keywords
Funding Information
- HORIZON EUROPE Health (101104589)
This publication has 60 references indexed in Scilit:
- Association of Remote Technology Use and Other Decentralization Tools With Patient Likelihood to Enroll in Cancer Clinical TrialsJAMA Network Open, 2022
- Current Challenges Faced by Cancer Clinical Trials in Addressing the Problem of Under-Representation of Older Adults: A Narrative ReviewOncology and Therapy, 2021
- Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trialsBreast Cancer Research and Treatment, 2021
- Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: a pooled analysis of randomised PALOMA clinical studiesEuropean Journal of Cancer, 2018
- Wearable Devices in Clinical Trials: Hype and HypothesisClinical Pharmacology & Therapeutics, 2017
- Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trialBreast Cancer Research and Treatment, 2017
- Improving the quality of survivorship for older adults with cancerCancer, 2016
- Slow accrual of elderly patients with metastatic breast cancer in the Dutch multicentre OMEGA studyThe Breast, 2013
- Association Between Age at Diagnosis and Disease-Specific Mortality Among Postmenopausal Women With Hormone Receptor–Positive Breast CancerJAMA, 2012
- Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trialsCancer, 2002